Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs
injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing
effect that produces pleurodesis, which is easy to cause severe chest pain despite of no
influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE.
Bevacizumab has been administrated locally in treating optic nerve sickness successfully by
anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in
treating MPE.